Oxford/AstraZeneca vaccine shows immune response in Phase 2 trial

The coronavirus vaccine being developed by the University of Oxford and AstraZeneca was found to be safe and triggers an immune response among all adults, according to preliminary findings of a peer-reviewed Phase 2 trial. CNBC's "Squawk Box" crew discuss.
Thu, Nov 19 20206:09 AM EST